Patent: 10,039,835
Summary for Patent: 10,039,835
| Title: | Bismuth containing liquid pharmaceutical suspensions |
| Abstract: | A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate. |
| Inventor(s): | Daniel Jerome White, Jr., Michael Selden Godlewski, Timothy Charles Gulbin, Graham John Myatt |
| Assignee: | Procter and Gamble Co |
| Application Number: | US15/289,445 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,039,835
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals (uk), Ltd. | ARCALYST | rilonacept | For Injection | 125249 | February 27, 2008 | 10,039,835 | 2036-10-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,039,835
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2015253188 | ⤷ Start Trial |
| Brazil | 112016025036 | ⤷ Start Trial |
| Canada | 2943422 | ⤷ Start Trial |
| China | 106456540 | ⤷ Start Trial |
| European Patent Office | 3137056 | ⤷ Start Trial |
| Mexico | 2016013886 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
